Physician profile
Emily Glazer
NPI 1881765014
$1,125.88
in general payments reported to CMS, 2019-2025
14 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $94.99 · 2023: $211 · 2024: $276 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $366.26 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.87 | 2019-2025 | Entyvio |
| Genzyme Corporation | $117.98 | 2023-2025 | |
| Ardelyx, INC. | $114.31 | 2024-2025 | Ibsrela |
| Pfizer INC. | $79.47 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $58.69 | 2019-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $43.04 | 2019-2020 | |
| Celgene Corporation | $34.88 | 2023 | Zeposia |
| Janssen Biotech, INC. | $24.12 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.87 | 2019 | |
| Braintree Laboratories, INC. | $20.79 | 2019 | |
| Shionogi INC | $18.54 | 2019 | |
| Madrigal Pharmaceuticals | $16.61 | 2025 | Rezdiffra |
| Allergan, INC. | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Glazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.